Antibodies that bind to two targets are a definite method for the treatment of multiple myeloma in hematologic cancer. To make these drugs stand out, Abbvie has secured the right to a drug that is bound by early stages of clinical practice that is bound with three goals.
The drug is coded ISB 2001 from Igi Therapeutics, an innovative subsidiary of Ichnos Glenmark. Abbvie said on Thursday that it would pay $700 million to cover the rights of multispecific T-cell participants such as North America, Europe, Japan and Greater China.
At the cell participant is an antibody drug that works by binding to a target on an immune cell and another target on a cancer cell, thus combining the two so that the immune cells can kill the cancer. IGI adds a third goal to overcome drug resistance in this approach. ISB 2001 is an engineered Trispific T-cell Engager that binds to CD3 on T cells and to BCMA and CD38 on multiple myeloma cells. Binding to two targets on multiple myeloma cells increases binding strength to cancer cells even when the target protein is expressed at low levels. It is also designed to reduce off-target adverse effects of therapy.
At the annual meeting of the American Society of Clinical Oncology last month, IGI presented data from the Phase 1 test of ISB 2001 in multiple myeloma patients with extensive pretreatment. The company reported that results from 35 patients showed a 79% sustained overall response rate for the drug and a 30% complete/strict complete response rate. The company said the safety of ISB 2001 is favorable; the cases of cytokine release syndrome are mild, and one case reported neurotoxicity is classified as Level 1.
The Tristific approach can have advantages over bispecific drugs currently available for multiple myeloma. Stability of Johnson & Johnson’s multiple myeloma products include Tecvayli, a bispecific drug that binds to CD3 on T cells and BCMA on cancer cells. Meanwhile, Pfizer’s Elrexfio is combined with CD38 and BCMA. The latest bispecificity for multiple myeloma is Lynozyfic from Regeneron Pharmaceuticals, a CD3 and togma targeted bispecific drug that was approved by the FDA last week.
“Multispecific antibodies, including specific antibodies, represent a new field in the field of immuno-oncology, and have the potential to provide a deeper, more durable response by engaging in multiple targets simultaneously,” said Abbvie Roopal Thakkar, vice president of research and development at Abbvie, Research and Development Officer Roopal Thakkar, Research and Chief Science Officer, Research and Chief Science Officer, in a prepared statement.
Based on the progress of ABBVIE’s ISB 2001, IGI could receive milestone payments of up to $1.225 billion, as well as royalties for the sale of approved drugs. The IGI drug represents Abbvie’s second multispecific transaction this year. In January, Abbvie signed an option completion agreement for Sim0500, a specific antibody of Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group. SIM0500 is designed to bind to CD3 on T cells, while GPRC5D and BCMA bind to multiple myeloma cells. This approach could make it a competitor to Talvey, a J&J bispecific antibody that binds to CD3 and GPRC5D.
Phase 1 tests in the United States and China are evaluating Simce medication in patients with relapsed or refractory multiple myeloma. Abbvie’s advance payment to Simcere is not disclosed. Option fees and milestone payments could cost more than $1 billion.
Photographer Abbvie
